Abstract
Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Reviews on Recent Clinical Trials
Title:What is the Current Role of Immunotherapy for Colon Cancer?
Volume: 11 Issue: 2
Author(s): Fernando Galanternik, Gonzalo Recondo, Matías E. Valsecchi, Martín Greco, Gonzalo Recondo, Máximo de la Vega and E. Diaz Cantón
Affiliation:
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Abstract: Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Export Options
About this article
Cite this article as:
Galanternik Fernando, Recondo Gonzalo, E. Valsecchi Matías, Greco Martín, Recondo Gonzalo, de la Vega Máximo and Diaz Cantón E., What is the Current Role of Immunotherapy for Colon Cancer?, Reviews on Recent Clinical Trials 2016; 11 (2) . https://dx.doi.org/10.2174/1574887111666160330121851
DOI https://dx.doi.org/10.2174/1574887111666160330121851 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cross-Talk between Tumor Cells and the Microenvironment at the Metastatic Niche
Current Pharmaceutical Biotechnology Micelles As Delivery System for Cancer Treatment
Current Pharmaceutical Design Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway
Current Cancer Drug Targets Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis
Current Drug Targets Variability in Reward Responsivity and Obesity: Evidence from Brain Imaging Studies
Current Drug Abuse Reviews Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry Endoglin Silencing has Significant Antitumor Effect on Murine Mammary Adenocarcinoma Mediated by Vascular Targeted Effect
Current Gene Therapy Coding and Non-coding: Molecular Portrait of GIST and its Clinical Implication
Current Molecular Medicine Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3
Anti-Cancer Agents in Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Recent Developments of Rebeccamycin Analogues as Topoisomerase I Inhibitors and Antitumor Agents.
Current Medicinal Chemistry The Medicinal Chemistry Implications of the Anticancer Effects of Aspirin and Other NSAIDs
Mini-Reviews in Medicinal Chemistry MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design